Read with a question in mind.
A source is most useful when you know what it can answer. An FDA page can describe an approval or a safety concern. A clinical paper can report what happened in the people it studied. Neither turns every similarly named product into the same medicine.
This is a small shelf, rather than a count of everything ever published. The compound guides carry their own focused links where a source helps the reader understand an important distinction.
Approval and safety information.
The FDA’s compounding safety page has separate tables. One is for ingredients in Category 2, a group with significant safety concerns. Another lists ingredients whose nominations were withdrawn. On the page current as of April 22, 2026, several familiar peptides appear in the withdrawn table. Withdrawal is not FDA clearance or approval. The safety concerns remain.
Approved-product safety information for semaglutide and tirzepatide is another kind of source. It concerns particular approved medicines. Compounded semaglutide and compounded tirzepatide are not FDA-approved, and those labels do not establish the safety of every compounded preparation.
The research question.
The FDA’s BPC-157 review is useful for its examination of limited human evidence and its safety concerns. Its epitalon review helps separate that peptide from epithalamin, an older gland extract. The similar names are a reminder to check exactly what was tested.
When reading any study, look for the population, the form of the ingredient, the comparison group and the outcome. A measurement in cells is not an outcome in a person. A trial finding is also not a prediction about one reader’s health.
Bring the reading back to the question.
A long reference list cannot replace a provider’s assessment. The point of reading is to understand the conversation, rather than to arrive with a prescription already decided. A licensed provider can weigh a person’s health history and explain why an option is inappropriate.
The writing and checking page explains our approach to these distinctions. If a word stops the flow, the glossary is nearby. For questions about a Promise consultation, its own support is the right destination.
